I Upgraded Rocket Lab to Buy — Expensive, Yes, but the Growth Story Still Has Legs

Hook & thesis

Rocket Lab just moved from high-growth speculative to high-growth company under the spotlight. The market has re-rated the shares aggressively after Q1 results and a flurry of contracts, pushing the stock into all-time high territory. That makes the stock more expensive today than it was a month ago, but I'm upgrading my view to Buy because the company's revenue momentum, backlog visibility and defense/customer wins materially reduce execution risk relative to the prior setup.

My take is pragmatic: valuation is stretched, so this is not a blind 'buy the breakout' call. It's a measured purchase sized for upside capture if Neutron proves out and the backlog converts, with defined risk management. I expect the next 180 trading days to be the proving ground for whether Rocket Lab's step-up to large-scale launch and integrated space systems is priced to perfection.

What Rocket Lab does and why the market should care

Rocket Lab operates across two core businesses: Launch Services (dedicated and rideshare launches) and Space Systems (spacecraft engineering, components, manufacturing and on-orbit operations). The point of investor interest is simple - the company is moving from selling single launches and components to offering vertically integrated mission solutions and a reusable medium-lift rocket (Neutron). That changes the unit economics and addressable market if Rocket Lab can scale.

Why this matters to markets: launch demand is rising (commercial and defense), recurring contracts increase revenue visibility, and a successful Neutron program would position Rocket Lab to serve larger payloads and capture higher-margin business. The company is also courting defense work: recent selections and a $30M hypersonic contract were highlighted alongside being chosen on the U.S. Space Force program.

Key facts and numbers

How the numbers support the buy

Two numbers stand out. First, Q1 revenue was ~$200.3M (a record quarter) and management reported a $2.2B backlog. Backlog-to-revenue conversion is the clearest path to de-risking the growth narrative: if Rocket Lab turns those contracts into launches over the next 12-36 months, the revenue base can scale meaningfully from today’s run-rate.

Second, the company has low leverage (debt to equity ~0.02) and healthy liquidity ratios that support ramp activity while they continue investing in Neutron and vertical integration. The cash balance per share is modest relative to the share price, but the balance sheet is not burdened by heavy debt. That matters for avoiding distress if execution hiccups occur.

That said, the valuation metrics are extreme: market cap is roughly $68B with price-to-sales above 100x. The market is pricing Rocket Lab like a company that will convert current backlog into a much larger recurring revenue stream and positive free cash flow within a relatively short time horizon. That's the thesis I am buying into here, but only with detailed risk controls.

Valuation framing

At a market capitalization of about $68B and price-to-sales of ~100x, Rocket Lab is trading at multiples typically reserved for highly profitable software franchises or dominant platform businesses. Rocket Lab is not there yet: EPS is negative (-$0.32) and free cash flow is negative ~-$316M. The current valuation can only be rationalized if revenue growth accelerates sharply and margin expansion follows — most likely tied to Neutron scaling and higher-margin space systems work.

Without peer multiples in this dataset, consider the logic: investors are paying for future mission volume, repeat customers (defense and constellation operators) and the optionality of Neutron. If Rocket Lab fails to scale Neutron or backlog conversion stalls, multiples will compress rapidly. Conversely, if Neutron succeeds and recurring launch cadence increases, today's valuation could look reasonable in hindsight.

Catalysts to watch (2-5)

• Neutron test program milestones culminating in a Q4 2026 test flight - success would materially re-rate prospects for scale.
• Quarterly backlog conversion and cadence of launches - consistent ramping of launch frequency turns backlog into revenue.
• Integration wins from the Motiv Space Systems acquisition and related supply-chain/robotics advantages.
• Additional defense contract awards and any commercial multi-launch deals that create recurring revenue.
• Market-wide catalyst: a SpaceX IPO could create a sector benchmark and force re-rating/pairs trading among pure-play launch providers (commentary from company CFO referenced this dynamic on 05/12/2026).

Trade plan - action you can take

I'm upgrading RKLB to Buy and initiating a position at the current price. Because the stock is richly valued and technically extended, this is a size-managed trade with explicit limits.

• Entry: $124.65 (current market price).
• Stop loss: $95.00. This level sits well below the recent short-term moving averages and provides room for normal volatility while limiting downside to a predefined loss.
• Target: $180.00 over a long-term horizon (180 trading days). This implies ~45% upside from the entry and reflects a scenario where backlog conversion and Neutron progress materially reduce execution uncertainty.
• Horizon: long term (180 trading days). I expect it will take multiple milestones — continued launch cadence, contract execution and at least one clear Neutron technical milestone — to justify the current valuation.

For traders who want a shorter plan: consider a mid-term take-profit at $150.00 over ~45 trading days to lock gains if the stock experiences post-earnings momentum without waiting for full demonstration of Neutron scalability.

Risks and counterarguments

• Valuation risk: The stock is priced for flawless execution. If revenue growth or margins disappoint, multiples compress fast given the current ~100x price-to-sales.
• Execution risk: Neutron development and test flights are complex. A delay, partial failure or higher-than-expected operating cost could derail the re-rating.
• Cash flow and funding risk: Free cash flow is negative (~-$316M). While leverage is low, continued cash burn could force equity raises at lower prices if ramp costs exceed expectations.
• Competition & customer concentration: SpaceX and traditional primes remain fierce competitors. Large customers can push for price or schedule concessions; losing a major customer or facing pricing pressure would hurt margins.
• Macro / market risk: A sector rotation (or a disappointing SpaceX IPO that shifts investor preference) could remove the premium on growth names and cause abrupt declines.

Counterargument: The clearest counter to my buy decision is that the market is correctly skeptical: Rocket Lab is still small on revenue and negative on cash flow, and paying software-like multiples for an aerospace manufacturer is perilous. If you believe margins and revenue cannot scale fast enough to justify that multiple within roughly a year, you should avoid the name or wait for a post-catalyst pullback.

What would change my mind

I would downgrade if one or more of the following occurs: (1) Neutron suffers a major test setback or multi-quarter delay; (2) backlog cancellations or materially extended delivery slippage emerge; (3) cash burn accelerates and management signals a dilutive capital raise; or (4) new data shows launch demand softening materially (commercial or defense). Conversely, I would add conviction if Rocket Lab posts sequential quarters of strong backlog conversion, positive operating leverage, and clear pathways to FCF positivity.

Conclusion

Rocket Lab is no longer the cheap optionality it was at much lower levels. The stock is expensive by conventional metrics, but the company has moved the needle on revenue, backlog and customer mix. That combination merits a tactical, risk-managed buy for investors who want exposure to the possible large upside of a successful Neutron program and recurring launch cadence. Keep positions sized to reflect the binary nature of aerospace milestones and use the stop and targets above to manage risk.

Trade idea snapshot: Initiate a long at $124.65, stop $95.00, target $180.00, horizon 180 trading days.